Qingyi granules ameliorate severe acute pancreatitis in rats by modulating the gut microbiota and serum metabolic aberrations

• Published in: Pharmaceutical biology 2023-12, Vol.61 (1), p.927-937
• Main Authors: Jiao, Juying, Liu, Jianjun, Luo, Fei, Shang, Mengxue, Pan, Chen, Qi, Bing, Zhao, Liang, Yin, Peiyuan, Shang, Dong
• Format: Article
• Language: English
• Subjects: Acute Disease; amylases; Animals; Biological Sciences; blood serum; carboxylic ester hydrolases; digestive system; Emodin; Enzyme-linked immunosorbent assay; Gastrointestinal Microbiome; Helicobacter; histopathology; inflammatory response; interleukin-6; Intestinal microflora; intestinal microorganisms; Lactobacillus; Metabolism; Metabolites; metabolome; Metabolomics; microbiome; Microbiota; multiomics; Pancreatitis; Pancreatitis - drug therapy; Pancreatitis - pathology; Rats; Rats, Sprague-Dawley; rRNA 16S; therapeutics; Traditional Chinese medicine; Tumor necrosis factor-α
• ISSN: 1388-0209; 1744-5116; 1744-5116
• DOI: 10.1080/13880209.2023.2222755

Qingyi granules can be used to effectively treat patients with severe acute pancreatitis (SAP). To elucidate the role of gut microbiota-mediated metabolism in the therapeutic effects of Qingyi granules. Sprague-Dawley rats were grouped into the sham operation, SAP model, Qingyi granule intervention (Q, 1.8 g/kg) and emodin intervention (E, 50 mg/kg) groups and observed for 24 h. H&E staining and ELISA were used for histopathological analysis and serum enzyme and cytokine assays. 16S rDNA sequencing and UHPLC-HRMS were used for gut microbiota analysis and untargeted metabolomics. In SAP rats, Qingyi granules decreased the pancreatic pathological score (Q, 7.4 ± 1.14; SAP, 11.6 ± 1.14, p